Russian courts are applying Article 54.1 with heightened scrutiny in pharmaceuticals. What in-house counsel needs to know. Make an enquiry.
Among the patterns that recur most frequently in Russian tax controversy work involving foreign pharmaceutical groups, one now stands out: the Federal Tax Service has identified the sector as a priority enforcement target under Article 54.1 of the Russian Tax Code, the unjustified tax benefit doctrine. Russian courts, applying the two-limb test introduced when Article 54.1 came into force, have produced a body of decisions that materially affects how foreign companies structure their Russian operations, supply chains, and intra-group arrangements. This comment examines a representative category of those decisions, identifies the reasoning that Russian courts have applied, and sets out the practical implications for in-house counsel managing Russian subsidiaries or distributor networks in the pharmaceuticals sector.
Article 54.1 of the Russian Tax Code replaced the judicially developed concept of unjustified tax benefit with a statutory framework. Under that framework, a taxpayer may not reduce its tax base or the amount of tax payable if the primary purpose of the transaction was to reduce tax rather than to achieve a legitimate commercial objective, or if the transaction was not in fact performed by the contractual counterparty. The Federal Tax Service has issued administrative guidance clarifying that both limbs must be assessed independently: a finding against the taxpayer on either is sufficient to disallow the claimed deduction or input VAT credit.
In the pharmaceuticals sector in Russia, the FTS has concentrated its scrutiny on three categories of arrangement. First, multi-tier distribution chains where the margin captured by intermediate entities lacks economic substance. Second, intra-group service arrangements, particularly marketing services, regulatory affairs support, and pharmacovigilance functions, where the documentation of actual service delivery is considered inadequate. Third, royalty and licence structures involving IP held outside Russia, where the FTS argues that the Russian operating entity is the genuine economic contributor and the foreign IP holder lacks the functions and assets to justify the royalty stream. These three categories share a common feature: the FTS challenges not the legal form of the arrangement but its economic substance, and Russian courts have in the main upheld those challenges.
In a category of decisions handed down across the past three to four years, Russian courts examining Article 54.1 disputes in the pharmaceuticals sector have articulated and consistently applied the following analytical framework. The court first asks whether the taxpayer can demonstrate that the transaction had a genuine commercial purpose independent of tax reduction. Where the taxpayer relies on documentation generated at or after the time of audit, courts have been consistently sceptical, finding that contemporaneous evidence of business purpose is required. The second limb of the analysis requires the court to verify that the contractual counterparty actually performed the services for which payment was made and a deduction or VAT credit claimed.
The courts have proved particularly attentive to a specific evidentiary gap that arises in the pharmaceutical context. Where a foreign group company provides services to a Russian subsidiary under an intercompany agreement, and the Russian entity claims corresponding deductions, courts have required detailed evidence of the service provider's headcount, qualifications, and functional involvement in the Russian market. In instances where that evidence was not produced in an organised and contemporaneous form, courts have characterised the payments as not reflecting a real economic transaction, triggering disallowance under the second limb of Article 54.1.
A further strand of reasoning concerns the relationship between Article 54.1 and transfer pricing rules. Courts have acknowledged that the two regimes are technically distinct, but have not treated a transfer pricing analysis as determinative of the Article 54.1 question. A price that falls within the arm's-length range may nonetheless be disallowed under Article 54.1 if the underlying transaction is found to lack substance. For foreign pharmaceutical groups whose Russian compliance posture has been organised primarily around transfer pricing documentation, this is the aspect of these decisions that carries the most immediate practical weight.
"In the pharmaceuticals sector, Russian courts have moved beyond pricing analysis entirely — the question is now whether the transaction happened at all in any economically meaningful sense, and taxpayers are being held to an evidentiary standard that catches many standard intra-group arrangements."
— Kristina Kornouhova, Senior Lawyer, Practice Lead — Tax & Antitrust, Vetrov & Partners
For in-house counsel managing Russian tax exposure in the pharmaceuticals sector, the shift in evidentiary standards described above makes early-stage advice essential — make an enquiry: info@vetrovpartners.com |
For in-house counsel at foreign pharmaceutical groups with Russian subsidiaries or distributor arrangements, the practical implications cluster around three areas.
The first is documentation. Russian courts have made clear that contemporaneous evidence of actual service performance is the primary battleground in Article 54.1 disputes. Correspondence, delivery reports, meeting records, and evidence of headcount at the service provider carry more weight than contractual terms or after-the-fact reconstructions. Groups whose intra-group arrangements rest primarily on framework agreements and annual invoices without underlying delivery documentation are carrying a material and underestimated exposure.
The second area is the substance of intermediate entities. Where a Russian group structure involves one or more entities between the foreign parent and the operating subsidiary, the FTS approach has been to examine whether those entities contribute economic functions that justify their position in the chain. Entities that lack staff, decision-making capacity, and independently verifiable functions are increasingly characterised as interposed without business purpose. Foreign groups that retain legacy holding or distribution structures from an earlier period of Russian operations may find that those structures are no longer defensible under current Article 54.1 case law, even where they were designed and documented carefully at inception.
The third implication is procedural. The limitation window for Russian tax assessments is material: the FTS may examine periods within a defined retrospective range, and the disallowance of deductions across multiple years can produce aggregate assessments of significant scale. Under Russian insolvency legislation, a subsidiary facing a tax assessment of this nature that it cannot discharge may be subject to creditor-initiated proceedings. For a foreign parent that has treated its Russian subsidiary as operationally self-sufficient, the arrival of a large retrospective tax assessment can require rapid engagement with both tax controversy and restructuring and insolvency advisers simultaneously.
In-house counsel reviewing this area should, as an immediate step, request a structured analysis of existing intra-group arrangements against the two-limb Article 54.1 test as applied by Russian courts. The Tax Controversy practice at Vetrov & Partners has prepared a framework for exactly this purpose, drawing on the case law discussed above and the FTS's published enforcement priorities for the sector.
If your group has Russian operations in the pharmaceuticals or life sciences sector and wishes to review Article 54.1 exposure, make an enquiry: info@vetrovpartners.com |
Q: What does this ruling change for foreign pharmaceutical companies with Russian operations?
A: The category of decisions discussed in this comment establishes, with notable consistency, that transfer pricing documentation is not a substitute for Article 54.1 substance analysis. Russian courts have held that a price within the arm's-length range does not automatically validate the underlying transaction. For foreign pharmaceutical groups, this means that intra-group service, royalty, and distribution arrangements that have been maintained primarily through transfer pricing compliance may face disallowance under Article 54.1 if the functional and documentary evidence of actual performance is not in order. The most immediate consequence is that groups should treat their existing TP documentation as a floor, not a ceiling, of their Russian tax defence posture.
Q: What should foreign companies do in light of this decision?
A: Three steps are advisable. First, commission a gap analysis of existing intra-group arrangements against the two-limb Article 54.1 test as applied by Russian courts — separately from any transfer pricing review. Second, review and strengthen the contemporaneous documentation of service delivery: correspondence, project records, evidence of personnel involvement, and delivery confirmation at the time of performance. Third, assess the retrospective exposure: identify which tax periods remain open for FTS examination and model the aggregate assessment risk if the current judicial approach is applied to those periods. The Tax Controversy practice at Vetrov & Partners can assist at each stage, including representation before the FTS and in matters before Russian courts.
This briefing is general information and does not constitute legal advice. For advice on a specific matter, write in confidence to info@vetrovpartners.com.
Our team advises foreign clients on exactly these questions across Russia and the EAEU region. Initial 30-minute consultation — complimentary.
Make an enquiry